Allogene Therapeutics (ALLO) Interest & Investment Income (2021 - 2026)

Allogene Therapeutics has reported Interest & Investment Income for 6 years, with the latest figure at $3.6 million in Q1 2026.

• Quarterly Interest & Investment Income fell 35.22% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.3 million (down 14.28% YoY) and the FY2025 annual result came in at $19.3 million, down 4.29% from the prior year.
• Interest & Investment Income eased to $3.6 million in Q1 2026 per ALLO's latest filing, from $3.7 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $6.7 million in Q3 2024 and troughed at $315000.0 in Q2 2022.
• A 5-year average of $3.9 million and a median of $3.8 million in 2023 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2024: Interest & Investment Income surged 1382.26% in 2022, then slumped 51.68% in 2024.
• Over 5 years, Interest & Investment Income stood at $2.8 million in 2022, then soared by 127.24% to $6.3 million in 2023, then plunged by 51.68% to $3.0 million in 2024, then rose by 20.91% to $3.7 million in 2025, then retreated by 2.38% to $3.6 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $3.6 million, $3.7 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.